Originally published as JCO Early Release 10.1200/JCO.2005.05.120 on July 11 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ducreux, M. Articles by Luboinski, M. Search for Related Content PubMed PubMed Citation Articles by Ducreux, M. Articles by Luboinski, M. Related Articles Related Editorial Social Bookmarking                            What's this?

Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer

From the Gastrointestinal Unit and Department of Public Health, Institut Gustave Roussy, Villejuif; Centre Val d’Aurelle, Montpellier; Centre Paul Papin, Angers; Centre Hospitalier de Colmar, Colmar; Centre Paoli Calmettes, Marseille; and Centre François Baclesse, Caen, France

Address reprint requests to Michel Ducreux, MD, PhD, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France; e-mail: ducreux{at}igr.fr

PURPOSE: Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs. Oxaliplatin combined with fluorouracil (FU) and leucovorin is effective in the treatment of colorectal cancer. In this context, a phase II study was conducted to evaluate concomitant administration of oxaliplatin by HAI and intravenous (IV) FU plus leucovorin according to the LV5FU2 protocol (leucovorin 200 mg/m², FU 400 mg/m² IV bolus, FU 600 mg/m² 22-hour continuous infusion on days 1 and 2 every 2 weeks).

PATIENTS AND METHODS: Patients had metastatic colorectal cancer that was restricted to the liver and inoperable. The patients were not to have previously received oxaliplatin. After surgical insertion of a catheter in the hepatic artery, patients were treated with oxaliplatin 100 mg/m² HAI combined with FU + leucovorin IV according to the LV5FU2 protocol. Treatment was continued until disease progression or toxicity. Response was evaluated every 2 months.

RESULTS: Twenty-eight patients were included, and 26 patients were treated. Two hundred courses of therapy were administered, and the median number of courses received was eight courses (range, zero to 20 courses). The most frequent toxicity consisted of neutropenia. The main toxicity related to HAI was pain. The intent-to-treat objective response rate was 64% (95% CI, 44% to 81%; 18 of 28 patients). With a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively.

CONCLUSION: The combination of oxaliplatin HAI and FU + leucovorin according to the LV5FU2 protocol is feasible and effective in patients presenting with isolated hepatic metastases of colorectal cancer.

Supported by a grant from Sanofi-Aventis, Paris, France.

Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases
  William D. Ensminger
  JCO 2005 23: 4815-4817 [Full Text]

This article has been cited by other articles:

				P. PILATI, E. MAMMANO, S. MOCELLIN, E. TESSARI, M. LISE, and D. NITTI Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy Anticancer Res, October 1, 2009; 29(10): 4139 - 4144. [Abstract] [Full Text] [PDF]

				D. G. Power and N. E. Kemeny The role of floxuridine in metastatic liver disease Mol. Cancer Ther., May 1, 2009; 8(5): 1015 - 1025. [Abstract] [Full Text] [PDF]

				D. G. Power and G. D. Leonard Hepatic Arterial Infusion: A Treatment at the "End of an Era"? J. Clin. Oncol., May 20, 2008; 26(15): 2597 - 2598. [Full Text] [PDF]

				S. Mocellin, P. Pilati, and D. Nitti In Reply J. Clin. Oncol., May 1, 2008; 26(13): 2232 - 2233. [Full Text] [PDF]

				H. Seki, T. Ozaki, and M. Shiina Side-Hole Catheter Placement for Hepatic Arterial Infusion Chemotherapy in Patients with Liver Metastases from Colorectal Cancer: Long-Term Treatment and Survival Benefit Am. J. Roentgenol., January 1, 2008; 190(1): 111 - 120. [Abstract] [Full Text] [PDF]

				S. Mocellin, P. Pilati, M. Lise, and D. Nitti Meta-Analysis of Hepatic Arterial Infusion for Unresectable Liver Metastases From Colorectal Cancer: The End of an Era? J. Clin. Oncol., December 10, 2007; 25(35): 5649 - 5654. [Abstract] [Full Text] [PDF]

				G. Portier, D. Elias, O. Bouche, P. Rougier, J.-F. Bosset, J. Saric, J. Belghiti, P. Piedbois, R. Guimbaud, B. Nordlinger, et al. Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial J. Clin. Oncol., November 1, 2006; 24(31): 4976 - 4982. [Abstract] [Full Text] [PDF]

				W. D. Ensminger A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases J. Clin. Oncol., August 1, 2005; 23(22): 4815 - 4817. [Full Text] [PDF]